indications for semaglutide 💊 NEW ORAL WEGOVY® (Semaglutide) – GPhC Exam Summary, 📌 Licensed for:, ✅ BMI ≥30 kg/m², OR, ✅ BMI ≥27 kg/m² + weight-related comorbidity (e.g. T2DM, HTN, dyslipidaemia, OSA), 🥗 Must be used with:, • Ozempic® (semaglutide) and Mounjaro™ (tirzepatide),

By preventing NFB from entering the cell nucleus, it reduces production of proinflammatory signals including TNF, IL1, IL6, and IL12

You may be affected by the class actions (a class member) if you are a Canadian who was prescribed one or more of the GLP-1 drugs listed below and you suffered serious problems such as gallbladder disorders, severe gastrointestinal problems (such as gastroparesis or bowel obstructions), blood clotting problems, intraoperative lung aspiration, necrotizing pancreatitis, vision loss, and malnutrition

The label also limits dosage in severe renal impairment

Li H, La S, Zhang X et al (2021) Salt-induced recruitment of specific root-associated bacterial consortium capable of enhancing plant adaptability to salt stress

Additional considerations include: Hypoglycemia : Low risk as monotherapy but increased when combined with insulin or sulfonylureas